SY-1425 induces maturation in RARA-high AML

Slides:

Advertisements

Similar presentations

AF647-RIS is internalized by TAMs in vivo.

Advertisements

by Benjamin J. Frisch, John M. Ashton, Lianping Xing, Michael W

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

AG-221 induces the differentiation of IDH2R140Q blasts along myeloid lineages in primary human AML xenograft models. AG-221 induces the differentiation.

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia by Donya Moradi Manesh, Jad El-Hoss, Kathryn.

NF1 silencing confers resistance of PC9 lung adenocarcinoma cells to erlotinib (erl). NF1 silencing confers resistance of PC9 lung adenocarcinoma cells.

Generation of Highly Cytotoxic Natural Killer Cells for Treatment of Acute Myelogenous Leukemia Using a Feeder-Free, Particle-Based Approach Jeremiah.

Effects of SC144 on in vivo ovarian tumor.

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia by Parvathi Ranganathan, Xueyan Yu, Caroline Na, Ramasamy Santhanam, Sharon Shacham,

B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.

CHK1 downregulation upon ERG overexpression.

COX-2–PGE2 signaling is required for MSC-induced increase in ALDHhigh CSC-enriched population and tumor initiation. COX-2–PGE2 signaling is required for.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Cytotoxic therapy induces CSF1-dependent macrophage recruitment.

AG-221 can reduce intracellular 2HG levels and induce differentiation in primary human IDH2R140Q- or IDH2R172K-mutant AML patient samples treated ex vivo.

Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells by Mia Eriksson, Pablo Peña-Martínez,

Myeloma cell–derived Runx2 promotes myeloma progression in bone

The therapeutic effects of HDAC and mTOR inhibitors are mediated by the suppression of class I HDACs and require oxidative stress. The therapeutic effects.

Core promoter methylation in mediators of adipogenesis.

CXCR5 expression accelerates Eμ-Tcl1 leukemogenesis and is indispensable for tumor cell recruitment to lymphoid B-cell follicles. CXCR5 expression accelerates.

mpJX-594 effects on tumor burden and leukocyte influx.

B cells infiltrate mouse and human pancreatic neoplasia and promote growth of KrasG12D-PDEC in vivo. B cells infiltrate mouse and human pancreatic neoplasia.

Nox1 as a potential therapeutic target to inhibit matricellular-mediated endothelial senescence. Nox1 as a potential therapeutic target to inhibit matricellular-mediated.

Volume 15, Issue 11, Pages (June 2016)

Silencing Ifngr1 in the CMT167 line confers decreased response to IFNγ in vitro and in vivo. Silencing Ifngr1 in the CMT167 line confers decreased response.

Inflammation is associated with increased basal-cell plasticity in the Nkx3.1 mutant prostate. Inflammation is associated with increased basal-cell plasticity.

Therapy-induced senescence of primary cells.

Comparison of conventional NSG and hIL-7 expressing NSG humanized mice

GIFT15 Bregs induce IL-10 expression in activated CD4+ T cells and enhance ex vivo formation of CD25+FoxP3+ Tregs from the spleen and CD49b+CD223+ Tr1s.

ABT-199 efficiently kills primary AML myeloblasts as a single agent.

Overexpression of IL-27 upregulates expression of multiple IR by T cells in vivo. Overexpression of IL-27 upregulates expression of multiple IR by T cells.

Stress-induced monocyte accumulation in the brain and the neurovascular induction of ICAM-1 were prevented by ADX. Male C57BL/6 mice were subjected to.

TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 has antileukemia activity in an in vivo primary AML xenograft.

Interacting MDSCs and mast cells (MC) in human colon carcinoma and in the colon of AOM/DSS-induced tumor-bearing mice. Interacting MDSCs and mast cells.

Protracted temozolomide (TMZ) treatment leads to acquired TMZ resistance in glioblastoma (GBM) cells in vivo. Protracted temozolomide (TMZ) treatment leads.

E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective breast tumors. E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective.

GS87 demonstrates efficacy in a circulating AML mouse model system.

Integrated mRNA and microRNA expression and DNA methylation clusters.

Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.

Antigen-specific CD8+ T cells express higher levels of PD-1 in animals that received the optimized SSX2 vaccine. Antigen-specific CD8+ T cells express.

BH3 profiling predicts venetoclax sensitivity in primary BPDCNs

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

In vivo AraC treatment does not induce any consistent changes in CD34+/−CD38+/− phenotypes nor in quiescent leukemic cells but increases apoptotic cell.

Bone marrow stroma partially protects multiple myeloma and AML cell lines from tipifarnib- and bortezomib-induced cell death. 8226/S myeloma cells were.

by Gonghua Huang, Yanyan Wang, Peter Vogel, and Hongbo Chi

ALT-803 stimulates proliferation and activation of human NK cells and T cells in vitro. ALT-803 stimulates proliferation and activation of human NK cells.

Cells lacking CDK6 kinase function are required to mutate p53.

Immunologic and pharmacokinetic studies.

ESKM is superior to ESK1 in vivo, and is effective against multiple tumor models. ESKM is superior to ESK1 in vivo, and is effective against multiple tumor.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

SY-1425 shows similar response in RARA-high AML cell lines to APL

Bortezomib induces an NRF2 signature and NRF2 protein in tumor cells from leukemic MCL. Gene sets regulated by bortezomib (Supplementary Tables S3 and.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Intratumoral changes in critical lymphocyte populations and numbers after NKTR-214 treatment. Intratumoral changes in critical lymphocyte populations and.

Mice treated with DC therapy and/or M-CSFR inhibition were protected from tumor rechallenge with combination therapy-treated mice displaying superior recall.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Targeted compounds exhibit cancer-selective ex vivo drug responses in AML. A, waterfall plot that highlights the most potent cancer-selective drugs for.

Constitutive expression of JAK3M511I and HOXA9 leads to development of both AML and T-ALL in vivo. Constitutive expression of JAK3M511I and HOXA9 leads.

Cabozantinib causes significant tumor cell elimination in vivo, but modest apoptosis induction in vitro. Cabozantinib causes significant tumor cell elimination.

GCS-100 selectively kills KRAS-addicted lung tumors.

Both TKI and EZH2i upregulate H3K27me3 targets, and combined treatment potentiates loss of LSCs. A, summary of global mean mRNA expression changes found.

The effect of βAR signaling on the generation of a cytotoxic CD8+ T-cell response in vivo. The effect of βAR signaling on the generation of a cytotoxic.

Ex vivo profiling of PD-1 blockade using MDOTS

SCLC PDX models recapitulate patient responses to an experimental therapy. SCLC PDX models recapitulate patient responses to an experimental therapy. A,

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

BH3-targeted inhibitors drive specific resistance in human cell lines, which can be overcome with alternating or combining inhibitors. BH3-targeted inhibitors.

Inhibition of MCL1 reduces AML in an in vivo murine model.

PD-L1 expression is not associated with PTEN expression status in melanomas. PD-L1 expression is not associated with PTEN expression status in melanomas.

Primary GBM cells are permissive to HCMV in vitro.

Presentation transcript:

SY-1425 induces maturation in RARA-high AML SY-1425 induces maturation in RARA-high AML. A and B, Histology from bone marrow for (A) SY-1425 treated and (B) vehicle treated. SY-1425 induces maturation in RARA-high AML. A and B, Histology from bone marrow for (A) SY-1425 treated and (B) vehicle treated. H&E staining of bone marrow from mice at day 14 of treatment shown at 100×. Inset on each image is Ki67 staining from the same bone marrow and time at 40×. C,CD38 mRNA expression analyzed by microarray in an APL cell line (NB-4; blue), a RARA-high cell line (MV4-11; red), and a RARA-low cell line (OCI-M1; gray). Error bars represent standard deviation of 3 biological replicates. D, CD38 protein expression analyzed by flow cytometry in an APL cell line (NB-4; blue), a RARA-high cell line (MV4-11; red), and a RARA-low cell line (OCI-M1; gray). Error bars represent standard deviation of 3 biological replicates. E, Plot of CD38-high induction for 3 RARA-high patients (left, red) and 2 RARA-low patients (right, blue) at indicated time points. Samples were mononuclear cells from patients with AML tested for ex vivo response to 50 nmol/L SY-1425. Michael R. McKeown et al. Cancer Discov 2017;7:1136-1153 ©2017 by American Association for Cancer Research